Anas Hadeh, MD
Pulmonary Disease · Weston, FLNPI 1437360187
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $539,847 of the $800,085 with a category attached, or 67.5%. 36 manufacturers reported payments, led by GSK at 49.9% of the total. 2025 is the largest year on record at $270,564, 6.4 times the $42,322 reported in 2019. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 912 payments — averaging $877.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$399K
- Insmed, Inc.$165K
- AstraZeneca$110K
- Sanofi$63K
- Grifols USA, LLC$26K
- Grifols Shared Services North America, Inc.$9K
- plus $28K from 30 others
Across 29 payments — averaging $1504.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mannkind Corporation$24K
- GSK$9K
- Chiesi USA, Inc.$9K
- Boehringer Ingelheim International GmbH$2K
What the payments were for
- Consulting fees$165,00321%
- Speaking & faculty fees$539,84767%
- Travel & lodging$63,7098%
- Food & beverage$31,4084%
- Education$1020%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 352 | $399,109 |
| Insmed, Inc. | 225 | $165,120 |
| AstraZeneca | 140 | $109,654 |
| Sanofi | 48 | $62,841 |
| Grifols USA, LLC | 20 | $25,794 |
| Grifols Shared Services North America, Inc. | 9 | $9,142 |
| Verona Pharma, Inc. | 9 | $9,066 |
| Regeneron Healthcare Solutions, Inc. | 8 | $4,244 |
| Boehringer Ingelheim | 23 | $4,193 |
| Mannkind Corporation | 2 | $3,699 |
| Nabriva Therapeutics, PLC | 2 | $1,784 |
| Merck | 2 | $1,502 |
| Inari Medical, Inc. | 4 | $690 |
| Actelion Pharmaceuticals US, Inc. | 9 | $509 |
| Genentech USA, Inc. | 5 | $406 |
| United Therapeutics Corporation | 8 | $400 |
| Baxter Healthcare | 5 | $228 |
| Mylan Specialty L.p. | 5 | $220 |
| Advanced Respiratory, Inc | 3 | $207 |
| Inspire Medical Systems, Inc. | 3 | $200 |
| Pulmonx Corporation | 2 | $164 |
| Mallinckrodt Enterprises LLC | 3 | $146 |
| Pharming Healthcare, Inc. | 1 | $125 |
| Amgen | 1 | $123 |
| Bayer | 1 | $109 |
| Mallinckrodt Hospital Products Inc. | 4 | $96 |
| Novartis | 5 | $79 |
| Philips North America LLC | 3 | $47 |
| AbbVie | 2 | $43 |
| Lungpacer Medical USA Inc | 1 | $31 |
| ERBE USA Inc | 2 | $25 |
| BD | 1 | $20 |
| Gilead | 1 | $19 |
| Ambu Inc. | 1 | $18 |
| Circassia Inc. | 1 | $18 |
| Pinnacle Biologics, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$800,085 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 19 | $289,952 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 123 | $88,167 |
| NucalaMepolizumab | 11 | $47,028 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $17,805 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 38 | $17,343 |
| Spiriva HandihalerTiotropium Bromide | 15 | $12,025 |
| ColistimethateColistin (Colistimethate Na) | 14 | $10,676 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $8,452 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $5,387 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,303 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $4,142 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 87 | $2,475 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,474 |
| Roflumilast | 24 | $2,472 |
| Advair DiskusFluticasone Propion/Salmeterol | 12 | $2,268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Insmed, Inc.Arikayce | $165,120 | $289,95219 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $399,109 | $181,269244 claims |
| AstraZenecaSymbicort | $109,654 | $5,38721 claims |
| Boehringer IngelheimStiolto Respimat | $4,193 | $5,30311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Weston
- Franck RahaghiWeston$1.2M
- David ZismanWeston$112K
- Roger AlvarezWeston$82K
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.